More than 10 Years and 6 million members later, the Brilliant Distinctions program is being relaunched with a new name and a new app: Allē. Arazlo Lotion 0.045%, the first lotion formulation of tazarotene, is now FDA approved for the topical treatment of acne vulgaris in patients nine years of age and older. The US affiliate of BTL Aesthetics has filed suit against Allergan and Germany’s Zimmer MedizinSysteme in the US Federal District Court for the District of Delaware, asserting that the Cooltone device infringes on BTL's US patents.
News | October 21, 2019
The FDA has approved Amzeeq (minocycline) topical foam, 4%, from Foamix Pharmaceuticals for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older....
News | October 18, 2019
Results from nine clinical trials of Foamix Pharmaceutical investigational products will be presented in five posters at the 39th Annual Fall Clinical Dermatology Conferencein Las Vegas. Findings relate FMX101 for the treatment of...
News | October 15, 2019
Altreno (tretinoin) Lotion, 0.05%, is now available exclusively for physician dispensing in a 20-gram size. Launched last year, Altreno Lotion from Ortho Dermatologics is the first and only tretinoin available in a lotion for...
In this week’s edition: Galderma’s Aklief (trifarotene) topical cream is now approved for acne. Sandra Johnson, MD weighs in. Supported by Sanofi and Regeneron in partnership with the National Eczema Association, the Understand AD Squad includes dermatologist Mercedes Gonzalez, MD, who discusses her experience. Sandy Klein, co-trustee of the Lynn Waxman Foundation, is this year’s Skin Cancer Foundation Champions for Change Honoree. The Hacking Dermatology 2019 Hackathon puts innovation front and center.
DermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
Going for the Gold: Sebacia Microparticles Help Direct Lasers to the Source of Acne